ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,770.20
0.55%
Dow Jones
42,801.72
0.52%
US Dollar vs MXN
20.26717
0.00%
Brent Oil
70.235
0.00%
Bitcoin
85,980.30
-0.20%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Genmab AS (GMAB)

  7. Genmab AS (GMAB) Noticias

GMAB

Genmab AS (GMAB)

Genmab AS
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:GMAB
FechaHoraFuenteTítuloSímboloCompañía
20/02/202507:00Business WireEPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular LymphomaNASDAQ:GMABGenmab AS
13/02/202512:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
12/02/202515:43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GMABGenmab AS
12/02/202512:06Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:GMABGenmab AS
09/12/202411:00Business WireTwo Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)NASDAQ:GMABGenmab AS
08/12/202410:00Business WireInvestigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary AnalysisNASDAQ:GMABGenmab AS
07/12/202418:00Business WireInvestigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)NASDAQ:GMABGenmab AS
05/11/202411:00Business WireGenmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual MeetingNASDAQ:GMABGenmab AS
15/09/202407:45Business WireInvestigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical TrialNASDAQ:GMABGenmab AS
19/08/202413:00Business WireTEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaNASDAQ:GMABGenmab AS
16/08/202408:00Business WireGenmab Announces Changes to its Executive CommitteeNASDAQ:GMABGenmab AS
28/06/202401:00Business WireEpcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular LymphomaNASDAQ:GMABGenmab AS
26/06/202418:08Business WireEPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)NASDAQ:GMABGenmab AS
03/06/202408:00Business WireInvestigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)NASDAQ:GMABGenmab AS
02/06/202416:30Business WirePreliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular LymphomaNASDAQ:GMABGenmab AS
01/06/202409:00Business WireInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)NASDAQ:GMABGenmab AS
23/05/202416:00Business WireGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:GMABGenmab AS
21/05/202410:10Business WireGenmab Completes Acquisition of ProfoundBioNASDAQ:GMABGenmab AS
14/05/202409:05Business WireGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) CongressNASDAQ:GMABGenmab AS
29/04/202417:40Business WireTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
29/04/202417:40Business WireFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
03/04/202400:35Business WireGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBioNASDAQ:GMABGenmab AS
01/03/202416:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GMABGenmab AS
27/02/202406:45Business WireU.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular LymphomaNASDAQ:GMABGenmab AS
02/02/202405:45Business WireTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
09/01/202406:45Dow Jones NewsPfizer, Genmab Get Speedy FDA Review of Tivdak Full ApprovalNASDAQ:GMABGenmab AS
09/01/202405:45Business WireTIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
09/01/202405:45Business WireTIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
09/12/202311:00PR Newswire (US)New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)NASDAQ:GMABGenmab AS
09/12/202311:00Business WireNew Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)NASDAQ:GMABGenmab AS
 Showing the most relevant articles for your search:NASDAQ:GMAB

Su Consulta Reciente

AMEX
XLV
Health Care Select Sector
CCOM
SILVER
SILVER
NASDAQ
GOOGL
Alphabet
AMEX
XLE
Energy Select Sector SPDR
NYSE
AXP
American Express
CCOM
US500
US 500
USOTC
RHHBY
Roche (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
FX
USDMXN
US Dollar vs MXN
NYSE
MRK
Merck
COIN
SOLUSD
Solana
CCOM
OILBRENT
Brent Oil
COIN
BTCUSD
Bitcoin
AMEX
SPY
SPDR S&P 500
COIN
ETHUSD
Ethereum
COIN
DOGEUSD
Dogecoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios